University's HIV diagnostic test expands into European market

November 07, 2005

A diagnostics test developed by the University of Liverpool for monitoring anti-HIV drugs in the blood is to be made available across Europe.

The test has been acquired by Delphic Europe - a diagnostics products provider - which will develop it in conjunction with viral resistance testing for market on the continent. The service was created by Professor David Back, Dr Saye Khoo and a team in the School of Biomedical Science and is currently used to analyse blood samples from patients with HIV across the UK in order to identify the correct dosage of medicine for individual patients.

Blood samples are routinely sent to Liverpool by 120 hospitals across the country and analysed to establish the amount of HIV drug in patients' blood. This enables doctors to identify the correct dosage for patients.

The service - the only one of its kind in the UK - examines 12 different drugs used by HIV patients. Assessing the amount of drug in the blood of an HIV patient is crucial as too much or too little can result in toxicity or therapy failure in a patient.

Professor Back said: "It is vital that our diagnostic test is made available to as many HIV patients as possible. Incorporation into Delphic is a very positive way forward for the service, effectively providing a 'one stop shop' for HIV diagnostics. The roll out into Europe will ensure that patients receive the most effective treatment to aid management of the disease."

Tim Leaver, Managing Director of Delphic, added: "Delphic is a revenue-generating business and is now ready to roll out its proven business model into the wider European market. We have the business, scientific and clinical leadership to capitalise on our existing products and to bring new diagnostics into our portfolio which will further enhance the potential for individualised care for HIV patients."
-end-
Notes to editors

1. An estimated 53,000 adults were living with HIV in the UK at the end of 2003, of whom 14,300 (27%) were unaware of their infection. In 2004, there were at least 6,973 new diagnoses of HIV, contributing to a total of 72,938 since the epidemic began.

2. As of the end of December 2003, there have been 280,664 reported AIDS diagnoses in Europe. At least 158,583 of these people have died. The 48 countries which have national HIV reporting systems have reported 571,648 HIV diagnoses. The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that more than two million people were living with HIV in Europe at the end of December 2004. Statistics according to AVERT, an international HIV and AIDS charity based in the UK.

3. The University of Liverpool is one of the UK's leading research institutions. It attracts collaborative and contract research commissions from a wide range of national and international organisations valued at more than £90 million annually.

University of Liverpool

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.